Table 4.
Outcome Parameters at BL (Baseline), T1 (Visit 1 Under Anti-IL-5 Therapy), T2 (Visit 2 Under Anti-IL-5Rα Therapy)
| BL | T1 | T2 | pBL-T1 | pT1-T2 | pBL-T2 | |
|---|---|---|---|---|---|---|
| ACT, points | 10 (8;13) | 16 (10;19) | 19 (14;22) | <0.001 | 0.005 | <0.001 |
| Pulmonary function tests, median (IQR) | ||||||
| FEV1% of predicted | 61 (41;74) | 61 (43;79) | 68 (49;87) | 0.1202 | 0.011 | 0.003 |
| FEV1 in mL | 1900 (1335; 2535) | 1970 (1260; 2495) | 1995 (1400; 2900) | 0.180 | 0.0556 | 0.0175 |
| FVC % of predicted | 79 (65;94) | 84 (68;100) | 85 (71;101) | 0.118 | 0.563 | 0.002 |
| RV % of predicted | 160 (133;182) | 153 (121;171) | 134 (113;163) | 0.4432 | 0.077 | 0.042 |
| TLC % of predicted | 109 (85;121) | 108 (94;123) | 110 (95;119) | 0.6518 | 0.1693 | 0.6518 |
| MEF25–75% of predicted | 33 (19;56) | 34 (16;53) | 47 (24;64) | 0.3 | 0.01 | 0.002 |
| eNO, ppb | 44 (22;85) | 41 (23;78) | 43 (25;66) | 0.2777 | 0.9842 | 0.4921 |
| Blood gases, median (IQR) | ||||||
| pO2, mmHg | 70 (65;85) | 71 (63;75) | 73 (65;86) | 0.511 | 0.2552 | 0.629 |
| pCO2, mmHg | 37 (34;39) | 37 (34;40) | 37 (34;39) | 0.7109 | 0.1958 | 0.2216 |
| Laboratory, median (IQR) | ||||||
| Blood eosinophils absolute (cells/µL) | 600 (400;1170) | 84 (27;152) | 7 (0;10) | <0.001 | <0.001 | <0.001 |
| IgE, IE/mL | 175 (63;402) | 101 (25;257) | 123 (25;277) | 0.790 | 0.061 | 0.091 |
| Number of exacerbations 12 months prior to and under therapy, mean (±SD) | 4.02 (±3.6) | 1.47 (±1.8) | 0.5 (± 1.3) | n/a | n/a | n/a |
| Number of annualized exacerbations, mean (±SD) | 4.02 (±3.6) | 1.88 (±2.2) | 1.1 (±3.5) |
<0.001 | <0.092 | <0.001 |
| Change of subjective condition under therapy, n (%) | n/a | n/a | n/a | |||
| Worsened | 4 (7) | 9 (15) | ||||
| Unchanged | 21 (35) | 15 (25 | ||||
| Improved | 33 (55) | 33 (55) | ||||
| Receiving daily OCS, n (%) | 41 (68) | 32 (53) | 19 (32) | <0.001 | 0.001 | <0.001 |
| OCS dose, mg/d | 10 (5;15) | 5 (2.5;10) | 0 (0;5) | <0.001 | 0.002 | <0.001 |
Note: For comparisons, Fisher’s exact test, Chi-squared test, Mann–Whitney U-test or two-sided paired t-test were used as appropriate.
Abbreviations: ACT, asthma control test; eNO, exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MEF, mean expiratory flow; n/a, not applicable; OCS, oral corticosteroids; RV, residual volume; TLC, total lung capacity.